A concerted effort to collect and bank tissues and biologic fluids from the upper respiratory tract has been an ongoing effort since 1990 under the direction of the Pathology Core leader. Initially, specimen collection primarily targeted overtly malignant carcinomas. Over time, the focus of specimen collection has shifted to tissues and biologic fluids representing much earlier stages along the tumor progression pathway and specimens from control patients without head and neck cancer. The availability of these tissues and cells has contributed to the work of many of the investigators participating in the SPORE, resulting over the years in significant discoveries with high translational impact and numerous peer-reviewed publications. The Pathology Core will continue to: 1) collect, store, process and distribute tissues and biologic fluids for translational research without compromise of patient care;2) provide well-characterized tumors with respect to site of origin, Worid Health Organization histologic subtype, differentiation, and fraction of neoplastic and stromal tissues;3) provide normal control tissue in addition to neoplasms;4) process and store tissues to address the requirements of all SPORE investigators;5) include neoplasms with a wide range of biologic potential (e.g. normal, dysplasia, carcinoma sequence);6) perpetuate tumor growth and expand tumor availability by xenografting tumors into immunodeficient mice;7) collect blood and exfoliated cells (e.g. oral rinses/oral brushes) from pertinent patients for the SPORE projects;8) provide the specimens in a timely fashion;and 9) provide well-defined mechanisms for prioritization of the distribution of requested resources to investigators within and external to the Johns Hopkins SPORE.

Public Health Relevance

The availability of high quality and well characterized human specimens is central and vital to translational research. The provisions of these specimens is imperative to the success of the SPORE projects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Specialized Center (P50)
Project #
5P50DE019032-13
Application #
8703531
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
13
Fiscal Year
2014
Total Cost
$269,475
Indirect Cost
$96,372
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Guo, Theresa; Sakai, Akihiro; Afsari, Bahman et al. (2017) A Novel Functional Splice Variant of AKT3 Defined by Analysis of Alternative Splice Expression in HPV-Positive Oropharyngeal Cancers. Cancer Res 77:5248-5258
Kang, Hyunseok; Tan, Marietta; Bishop, Justin A et al. (2017) Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma. Clin Cancer Res 23:283-288
Bishop, Justin A; Westra, William H (2017) MYB Translocation Status in Salivary Gland Epithelial-Myoepithelial Carcinoma: Evaluation of Classic, Variant, and Hybrid Forms. Am J Surg Pathol :
Zhang, Hongzheng; Kim, Sungjin; Chen, Zhengjia et al. (2017) Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma. Head Neck 39:2433-2443
Bishop, Justin A; Rooper, Lisa M; Chiosea, Simion I et al. (2017) Clear Cell Carcinoma of Salivary Glands is Frequently p16 Positive: A Pitfall in the Interpretation of Oropharyngeal Biopsies. Am J Surg Pathol :
Anagnostou, Valsamo; Smith, Kellie N; Forde, Patrick M et al. (2017) Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Cancer Discov 7:264-276
Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2017) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 15:179-188
Peri, Suraj; Izumchenko, Evgeny; Schubert, Adrian D et al. (2017) NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nat Commun 8:1772
Weidhaas, Joanne B; Harris, Jonathan; Schaue, Dörthe et al. (2017) The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 3:483-491
Guerrero-Preston, Rafael; White, James Robert; Godoy-Vitorino, Filipa et al. (2017) High-resolution microbiome profiling uncovers Fusobacterium nucleatum, Lactobacillus gasseri/johnsonii, and Lactobacillus vaginalis associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and Oncotarget 8:110931-110948

Showing the most recent 10 out of 122 publications